Theranostics is a groundbreaking topic that's reshaping how we diagnose and treat cancer. It's a cutting-edge approach in cancer care, combining diagnosing and treating cancer using the same molecular tools. Theranostics has the spotlight because it's delivering on a promise we've been chasing for years in cancer care, truly personalized targeted treatment with fewer side effects than traditional options.

Guests:

Lindsay Williams, MBA, CNMT, R.T.(N)(CT)(ARRT)

Pharmacy Sourcing Portfolio Executive

Vizient

Setu Shah, MPH

Sr. Associate, Intelligence

Sg2

Janna Laton, MBA, CNMT, NMTCB(CT), R.T.(R)(N)(MR)(ARRT)

Independent Contributor and SME

Host:

Adam Fairbourn, MBA, CNMT

Senior Director, Contract Services

Vizient, Capital Equipment Solutions

Show Notes:

[00:48 – 01:55] What it takes for a healthcare organization to implement Theranostics

[01:56 – 04:04] Success stories solving for some of the access and workflow issues

[04:05 – 05:11] Education and training programs needed to support demand for nuclear medicine specialists and technologists

[05:12 – 07:54] What's driving that growth in the field

[07:55 – 09:34] What’s most exciting about theranostics over the next five to 10 years

[09:34– 10:08] Will Theranostics become the standard of care for more types of cancer than we see today

[10:09 – 11:30] The future of cancer care and Theranostics

[11:30– 12:03] What Vizient is doing on the Theranostics front

Links | Resources:

Vizient article - https://www.vizientinc.com/insights/diagnostic-imaging

Sg2 Perspectives Podcast: Transforming Cancer Care Delivery

Sg2 Perspectives Podcast: Cell and Gene Therapy in Practice

Subscribe Today!

Apple Podcasts

Spotify

YouTube

RSS Feed